Abstract
Background
The relative prevalence of myasthenia gravis (MG) subtypes is changing, and their differential features and association with HLA class II alleles are not completely understood.
Methods
Age at onset, presence/absence of autoantibodies (Ab) and thymoma were retrospectively considered in 230 adult Italian patients. Clinical severity, assessed by MGFA scale, and the highest Ab titer were recorded. Furthermore, we performed low/high resolution typing of HLA-DRB1 and HLA-DQB1 alleles to detect associations of these loci with MG subtypes.
Results
There were two peaks of incidence: under 41 years of age, with female preponderance, and over 60 years, with higher male prevalence. The former group decreased and the latter increased significantly when comparing onset period 2008–2015 to 2000–2007. Thymomatous (TMG) patients showed a higher prevalence of severe phenotype and significantly higher anti-AChR Ab titer than non-thymomatous (NTMG) patients. Among the latter, those with onset after 60 years of age (LO-NTMG) displayed significantly higher Ab titers but lower MGFA grade compared to early-onset patients (< 41 years; EO-NTMG). Significant associations were found between HLA DQB1*05:01 and TMG patients and between DQB1*05:02 and DRB1*16 alleles and LO-NTMG with anti-AChR Ab.
Conclusions
Two distinct cutoffs (< 41 and > 60 years) conveniently define EO-NTMG and LO-NTMG, with different characteristics. LO-NTMG is the most frequent disease subtype, with an increasing incidence. TMG patients reach higher clinical severity and higher antibody titers than NTMG patients. Moreover, TMG and LO-NTMG with anti-AChR Ab differ in their HLA-DQ association, providing further evidence that these two forms may have different etiologic mechanisms.
Similar content being viewed by others
References
Carr A (2015) Actual world epidemiology of myasthenia gravis. In: Mineo TC (ed) Novel challenges in myasthenia gravis. Nova Science Publisher Inc, New York, pp 23–43
Casetta I, Groppo E, De Gennaro R et al (2010) Myasthenia gravis: a changing pattern of incidence. J Neurol 257:2015–2019
Montomoli C, Citterio A, Piccolo G et al (2012) Epidemiology and geographical variation of myasthenia gravis in the province of Pavia, Italy. Neuroepidemiology 38:100–105
Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Ströbel P (2013) The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 12:875–884
Alkhawajah NM, Oger J (2013) Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing. Muscle Nerve 48:705–710
Seldin MF, Alkhairy OK, Lee AT et al (2015) Genome-wide association study of late-onset myasthenia gravis: confirmation of TNFRSF11A and identification of ZBTB10 and three distinct HLA associations. Mol Med 21:769–781
Renton AE, Pliner HA, Provenzano C et al (2015) A genome-wide association study of Myasthenia Gravis. JAMA Neurol 72:396–404
Poulas K, Zagoriti Z, Kambpouris M, Lagoumintzis G (2015) Advanced Genetics in Myasthenia Gravis. In: Mineo TC (ed) Novel challenges in myasthenia gravis. Nova Science Publisher Inc, New York, pp 109–132
Testi M, Terracciano C, Guagnano A et al (2012) Association of HLA-DQB1*05:02 and DRB1*16 Alleles with Late-Onset, Nonthymomatous, AChR-Ab-Positive Myasthenia Gravis. Autoimmune Dis 2012:541760
Evoli A, Antonini G, Antozzi C et al (2019) Italian recommendations for the diagnosis and treatment of myasthenia gravis. Neurol Sci (in press)
Klein R, Marx A, Ströbel P, Schalke B, Nix W, Willcox N (2013) Autoimmune association and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis. Hum Immunol 74:1184–1193
Evoli A, Caliandro P, Iorio R et al (2015) Poly-autoimmunity in patients with myasthenia gravis: a single-center experience. Autoimmunity 48:412–417
Somnier FE (2005) Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 65:928–930
Agius MA, Richman DP, Vincent A (2009) Autoantibody testing in the diagnosis and management of autoimmune disorders of neuromuscular transmission and related disorders. In: Kaminski HJ (ed) Myasthenia gravis and related disorders, 2nd edn. Humana Press, New York, pp 143–156
Murai H, Yamashita N, Watanabe M et al (2011) Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci 305:97–102
Maniaol AH, Elsais A, Lorentzen AR et al (2012) Late Onset myasthenia gravis is associated with HLA DRB1*15:01 in the norwegian population. PLoS One 7:e36603
Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B (2014) Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmunity 48–49:143–148
Akaishi T, Yamaguchi T, Suzuki Y et al (2014) Insights into the classification of Myasthenia gravis. PloS ONE 9:e106757
Howard FM Jr, Lennon VA, Finley J, Matsumoto J, Elveback LR (1987) Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in Myasthenia gravis. Ann N Y Acad Sci 505:526–538
Kang SY, Oh JH, Song SK, Lee JS, Choi JC, Kang JH (2015) Both binding and blocking antibodies correlate with disease severity in myasthenia gravis. Neurol Sci 36:1167–1171
Vandiedonck C, Raffoux C, Eymard B et al (2009) Association of HLA-A in autoimmune Myasthenia gravis with thymoma. J Neuroimmunol 210:120–123
Bartoccioni E, Scuderi F, Augugliaro A et al (2009) HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 72:195–197
Nikolic AV, Andric ZP, Simonovic RB et al (2015) High frequency of DQB1*05 and absolute absence of DRB1*13 in muscle-specific tyrosine kinase positive myasthenia gravis. Eur J Neurol 22:59–63
Baggi F, Antozzi C, Andreetta F et al (1998) Identification of a novel HLA class II association with DQB1∗0502 in an Italian myasthenic population. Ann N Y Acad Sci 841:355–359
Saruhan-Direskeneli G, Hughes T, Yilmaz V et al (2016) Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis. Clin Immunol 166–167:81–88
Ayyar BV, Atassi MZ (2017) Development of humanized scFv antibody fragment(s) that targets and blocks specific HLA alleles linked to myasthenia gravis. Appl Microbiol Biotechnol 101:8165–8179
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethical standards
The study protocol was approved by the Independent Ethic Committee of PTV and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Informed consent
All participating subjects signed an informed consent.
Additional information
Roberto Massa and Giulia Greco authors contributed equally to the work.
Rights and permissions
About this article
Cite this article
Massa, R., Greco, G., Testi, M. et al. Thymomatous myasthenia gravis: novel association with HLA DQB1*05:01 and strengthened evidence of high clinical and serological severity. J Neurol 266, 982–989 (2019). https://doi.org/10.1007/s00415-019-09225-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-019-09225-z